Walleye Capital
BCRX icon

Walleye Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Sell
20,878
-5,915
-22% -$53.5K ﹤0.01% 3477
2026
Q1 		$255K Sell
26,793
-224,877
-89% -$1.75M ﹤0.01% 3178
2025
Q4 		$1.96M Buy
251,670
+24,606
+11% +$178K 0.01% 1889
2025
Q3 		$1.72M Sell
227,064
-2,073,564
-90% -$17.3M 0.01% 1687
2025
Q2 		$20.6M Buy
2,300,628
+2,145,936
+1,387% +$20M 0.08% 219
2025
Q1 		$1.16M Sell
154,692
-204,830
-57% -$1.65M 0.01% 1852
2024
Q4 		$2.7M Buy
359,522
+100,140
+39% +$760K 0.01% 1500
2024
Q3 		$1.97M Buy
259,382
+50,557
+24% +$384K ﹤0.01% 1966
2024
Q2 		$1.29M Buy
208,825
+145,073
+228% +$801K ﹤0.01% 2572
2024
Q1 		$324K Sell
63,752
-650,706
-91% -$3.66M ﹤0.01% 3593
2023
Q4 		$4.28M Buy
714,458
+3,807
+0.5% +$22.1K 0.01% 1205
2023
Q3 		$5.03M Buy
710,651
+534,472
+303% +$3.84M 0.01% 1035
2023
Q2 		$1.24M Buy
176,179
+166,635
+1,746% +$1.34M ﹤0.01% 1667
2023
Q1 		$79.6K Sell
9,544
-595,989
-98% -$5.74M ﹤0.01% 3042
2022
Q4 		$6.95M Buy
605,533
+364,119
+151% +$4.54M 0.13% 197
2022
Q3 		$3.04M Buy
241,414
+181,816
+305% +$2.34M 0.06% 362
2022
Q2 		$631K Sell
59,598
-122,969
-67% -$1.27M 0.02% 904
2022
Q1 		$2.97M Buy
+182,567
New +$2.93M 0.08% 258
2021
Q4 		– Sell
-41,131
Closed -$591K – 2100
2021
Q3 		$591K Buy
41,131
+27,173
+195% +$429K 0.02% 715
2021
Q2 		$221K Buy
+13,958
New +$190K 0.01% 1037
2020
Q2 		– Sell
-156,507
Closed -$313K – 619
2020
Q1 		$313K Buy
156,507
+53,157
+51% +$146K 0.07% 332
2019
Q4 		$357K Buy
+103,350
New +$260K 0.02% 840

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Walleye Capital's BCRX Position: Q2 2026 in Review

Walleye Capital reduced its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q2 2026, selling an estimated $53.5K and leaving 20,878 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

Walleye Capital first reported a position in BCRX in Q4 2019 and has held it in 22 quarters since. The position peaked at $20.6M in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Walleye Capital held 20,878 shares of BioCryst Pharmaceuticals worth $209K as of Q2 2026.
  • Walleye Capital sold 5,915 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $53.5K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3477 holding.
  • Walleye Capital first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • Walleye Capital's BioCryst Pharmaceuticals position peaked at $20.6M in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.